Matthew Herper at Forbes argues that the biotech boom of the past two years has been spurred by new drug launches and research breakthroughs. However, he cautions that some investors are currently "seeing rainbows and missing the rain."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Related Posts

The One to Beat

Sewer Sequences

23andMe's Data Deal

Going Big

In Nature this week: omic analysis of permafrost microbes, hookworm genome, and more.

Biologists turn to environmental DNA sampling to determine whether elusive or invasive species are shedding DNA in a given area.

Rob Knight writes at Scientific American that microbiome studies are about to break out of the laboratory.

Harold Varmus, the director of the National Cancer Institute, has announced that he is stepping down after nearly five years.